CClinicalTrials.gg
CompletedNCT02865096Updated Dec 7, 2017

The Correlation of Women's Sexual Health and Marijuana Use

An observational study in Women's Sexual Health, sponsored by St. Louis University. Completed at 1 site in United States. Open to female participants aged 18 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-12-07.

Sponsored by St. Louis University · Observational

Study type
Observational
Model
Ecologic or community
Time perspective
Prospective
Enrollment
373
Ages
18 Years to 90 Years
Sex
Female
01

Study summary

This study is attempting to determine whether there is any effect (worsening or improvement of sexual function) after marijuana consumption. Both users and non users of marijuana will be given the opportunity to participate by completing a questionnaire.

Read the detailed description

Marijuana is the most commonly used illicit drug (19.8 million past-month users) according to the 2013 National Survey on Drug Use and Health (NSDUH).

There is a current movement towards the legalization of marijuana in various states and there are numerous claims of potential uses in medicine.

The internet is rich with nonscientific, non-evidence based information regarding the effects of marijuana on the sex lives of women. However, surprisingly little scientific research has been done on it.

Cannabis use and sexual function Endocannabinoids, which are structurally similar to cannabis (marijuana) help regulate a number of motivated behaviors and emotional states, including sexual function. There are a variety of ways that cannabinoids interact with the hormones and neurotransmitters that affect sexual behavior. This interaction has not been clearly elucidated but studies in rats have helped to clarify the relationship between cannabinoids and the hormones and neurotransmitters that affect sexual behavior.

In male rats, administration of tetrahydrocannabinol (THC, the psychoactive compound in marijuana) reduced sexual motivation. In female rats, the relationship between THC and sexual behavior is less clear. found that giving female rats a low dose of THC increased their receptivity to copulation. However a high dose interfered with receptivity, also found that THC stimulated receptivity and increased proceptivity ("courting behavior") in female hamsters.

Lopez et al found that in rats, giving a cannabinoid receptor blocker, increased sexual motivation during the estrous cycle. They then found that ovariectomized rats given a cannabinoid receptor agonist, had reduced sexual motivation. When exogenous estrogen and progesterone were given, this effect was attenuated.

The exact mechanism by which THC affects sexual function in women is unknown. It is known that THC and the hypothalamic-pituitary-gonadal (HPG) axis, which controls the sex hormones, interact with eachother. Acute administration of THC has been shown to inhibit LH and PRL secretion from the anterior pituitary in males and females. In females, high dose of THC can interfere with estrous and menstrual cycle timing and can delay or prevent ovulation. Cannabinoids inhibit or interfere with activity of the HPG axis and reduce secretion of several hormones which tend to have an inhibitory impact on sexual behavior.

It is known that dopamine is a key prosexual modulator in normal excitatory female sexual function. It is also known that the major effects of THC in the central nervous system are mediated by cannabinoid receptors. These receptors have been shown to enhance dopamine (Lazenka et al, 2015), which may be another pathway by which marijuana affects sexual function.

Human studies are limited. Questioned regular male and female marijuana users about their opinions regarding changes in the sexual experience when using marijuana. They found that when marijuana affects the sexual experience, it affects it positively. Marijuana did appear to increase desire mildly and enhances the quality of orgasm.

There are several links between THC and hormonal and neurotransmitter pathways that play a role in sexual function and dysfunction, providing a theoretical way that THC may alter sexual functioning. These links need to be more clearly studied and elucidated.

02

Conditions studied

  • Women's Sexual Health

Browse trials for

03

In context

Marijuana Use

56 studies on the registry are indexed under Marijuana Use; 6 are open to participants now.

Browse Marijuana Use studies →

Lead sponsor

St. Louis University is the lead sponsor of 152 studies on the registry; 17 are open to participants now.

Of its 19 completed or terminated interventional studies of FDA-regulated products, 15 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Patient participants will be asked upon check-in at their ob/gyn office whether they would like to participate in the questionnaire study. Patients will be asked to complete their questionnaire in the exam room of the ob/gyn practice. Patients who choose to voluntarily participate in the study, will be instructed to place their anonymous questionnaire in a provided blank envelope and seal it as to ensure confidentiality, then return their completed questionnaire to the front desk and place the sealed envelope in a lock box themselves.

Inclusion criteria

Female ages 18 to 90 years old, agree to fill out questionnaire

Exclusion criteria

Exclusion Criteria:

Male, Female age less than 18 or over 90 years old, decline to fill out questionnaire

05

Study design

Observational model
Ecologic or community
Time perspective
Prospective
Enrollment
373 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Evaluate the relationship between marijuana consumption and sexual function

    Study participants will fill out one anonymous questionnaire and deposit the completed questionnaire themselves in a locked box.

    Time frame: 1 day

07

Study locations

1 site
  • St. Mary's Health Center
    Saint Louis, Missouri 63117, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 7, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02865096
Lead sponsor
St. Louis University
Responsible party
Becky Lynn, MD (MD, St. Louis University) — Principal investigator
First posted
Aug 12, 2016
Start date
Mar 1, 2016
Primary completion
Feb 1, 2017
Completion
Feb 1, 2017
Last update
Dec 7, 2017

Study contacts

Becky Lynn, MD
principal investigator · St. Louis University

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion